½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : ±â¼úº°, Á¦Ç°º°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° µ¿Çâ(2024-2030³â)
Real-time PCR, Digital PCR, And End-point PCR Market Size, Share & Trends Analysis Report By Technology (Quantitative, Digital, End-point), By Product, By Application, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1405904
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,245,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,631,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,402,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, IncÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é Àü ¼¼°è ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 4.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. 71¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª Äڷγª19 ÆÒµ¥¹ÍÀÇ ¿µÇâÀ» Á¦¿ÜÇÑ ½ÇÁ¦ ¼¼°è ½Ç½Ã°£ PCR, µðÁöÅÐ PCR, ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö 8.7%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µðÁöÅÐ PCRÀº À¯»çÇÑ ´Ù¼öÀÇ ¼­¿­ÀÌ Á¸ÀçÇÒ ¶§ ¼Ò¼ö ¼­¿­À» Àý´ëÀûÀ¸·Î Á¤·®È­ÇÏ°í ºÐ¼®ÇÏ´Â »õ·Î¿î ±â¼úÀ̸ç, dPCRÀº Á¤È®ÇÏ°í ¹Î°¨ÇÑ ÇÙ»ê ÃøÁ¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ PCRÀº Áúº´ÀÇ Á¤È®ÇÑ Á¶±â Áø´ÜÀ» Á¦°øÇÏ¿© ½Å¼ÓÇϰí Á¤È®ÇÑ È¯ÀÚ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù.

Æó¾Ï, Ç÷¾×¾Ï, ³úÁ¾¾ç°ú °°Àº Áúº´ Áõ°¡´Â ¼¼°è ½ÃÀå¿¡¼­ÀÇ Àû¿ë È®´ë¸¦ ÃËÁøÇϰí ÀÖÀ¸¸ç, Globocan 2020¿¡ µû¸£¸é Æó¾ÏÀº À¯·´¿¡¼­ µÎ ¹øÂ°·Î ÈçÇÑ ¾ÏÀ¸·Î 477,534°ÇÀÇ ½Å±Ô Áø´ÜÀ» ¹ÞÀº °ÍÀ¸·Î Ãß»êµË´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ ¹× Á¤·®Àû ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ°ú °°Àº ±âÁ¸ ±â¼ú¿¡ ºñÇØ µðÁöÅÐ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀÀÇ ÀåÁ¡Àº ¿¹Ãø ±â°£ µ¿¾È äÅÃÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í Á¤È®ÇÑ ºÐÀÚ Áúȯ °ËÃâ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Äڷγª19ÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ µðÁöÅÐ PCR Àåºñ¿Í ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, Äڷγª19 °¨¿°Àº ÃֽеðÁöÅÐ PCR Àåºñ¸¦ ÅëÇØ ºÐÀÚÁø´Ü ±â¼ú·Î °ËÃâµÇ°í ÀÖ½À´Ï´Ù. È®ÁøÀÚ°¡ ¹ß»ýÇß°í, ¾à 530¸¸ ¸íÀÌ »ç¸ÁÇÑ °ÍÀ¸·Î Áý°èµÆ½À´Ï´Ù. ¶ÇÇÑ Á¦¾à ¾÷°è¿¡¼­´Â µðÁöÅÐ PCR Àåºñ°¡ ¿¬±¸°³¹ß¿¡µµ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ±â¼ú ¹ßÀü°ú ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¦Ç° Ãâ½Ã Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 6¿ù Bio-Rad Laboratories, Inc.´Â Äڷγª19 Æó¼ö °Ë»ç¸¦ À§ÇÑ PREvalence ddPCR SARS-CoV-2 Æó¼ö Á¤·® ŰƮ Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

¶ÇÇÑ, ±â¼ú ¹ßÀüÀ» À§ÇÑ R&D ÇÁ·ÎÁ§Æ® Áõ°¡¿Í µðÁöÅÐ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ °³¹ßÀ» À§ÇÑ ±â¾÷ °£ Çù·Â °ü°è Áõ°¡´Â PCR °Ë»çÀÇ È°¿ëÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, Ű¾ÆÁ¨Àº 2022³â 1¿ù Attila BioSystems &Actome GmbH¿Í Á¦ÈÞÇÏ¿© ºñħ½ÀÀû »êÀü°Ë»ç(NIPT) ±â¼úÀ» QIAGENÀÇ dPCR¿¡ Á¦°øÇÔÀ¸·Î½á QIAcuityÀÇ ¿ëµµ ¼ö¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ±× °á°ú, ½Ç½Ã°£ PCR ¹× µðÁöÅÐ PCR ±â¼úÀÇ »ç¿ëÀº ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå º¸°í¼­ÀÇ ÁÖ¿ä ³»¿ë:

  • ±â¼úº°·Î´Â Á¤·®Àû PCR ºÎ¹®ÀÌ 2023³â 83.34% ÀÌ»óÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Äڷγª19 ¼±º° ¹× Áø´ÜÀ» À§ÇÑ ½Ç½Ã°£ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀÀ» ±â¹ÝÀ¸·Î ÇÑ Á¦Ç° µµÀÔ Áö¿ø ±â¼úÀÇ ³ôÀº äÅÿ¡ ±âÀÎÇÕ´Ï´Ù.
  • ¼Ò¸ðǰ ¹× ½Ã¾à ºÎ¹®Àº Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í µðÁöÅÐ PCR ¼Ò¸ðǰ ¹× ½Ã¾àÀ» Á¦Á¶ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ ¼ö·Î ÀÎÇØ 2023³â 62.62% ÀÌ»óÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ºÏ¹Ì´Â ³ôÀº R&D ÅõÀÚÀÇ Á¸Àç, ±â¼úÀûÀ¸·Î Áøº¸µÈ ÇコÄÉ¾î ¿¬±¸ ÇÁ·¹ÀÓ¿öÅ©ÀÇ °¡¿ë¼º, Àú¸íÇÑ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ Á¦Á¶¾÷üÀÇ °­·ÂÇÑ Á¸Àç, ÀÌ Áö¿ªÀÇ ½Å¼ÓÇÑ Áø´Ü Å×½ºÆ®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2023³â 35.94% ÀÌ»óÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

    ¸ñÂ÷

    Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

    Á¦2Àå ÁÖ¿ä ¿ä¾à

    Á¦3Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå - ¾÷°è Àü¸Á

    • ½ÃÀå °èÅë Àü¸Á
    • ½ÃÀå ¿ªÇÐ
    • ºñ±³ ÇØ¼®
    • SWOT ºÐ¼®, ¿äÀκ°(Á¤Ä¡¡¤¹ý·ü, °æÁ¦¡¤±â¼ú)
    • ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®

    Á¦4Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, ±â¼ú ¹üÀ§, 2018³â-2030³â

    • ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå : ±â¼ú º¯µ¿ ºÐ¼®
    • Á¤·®Àû
      • Á¤·®ÀûÀÎ ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ±â±â
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º
    • µðÁöÅÐ
      • µðÁöÅÐ ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ±â±â
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º
    • ¿£µåÆ÷ÀÎÆ® PCR
      • ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ±â±â
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

    Á¦5Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, Á¦Ç° ¹üÀ§, 2018³â-2030³â

    • ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
    • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ¼Ò¸ðǰ ¹× ½Ã¾à ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
    • ±â±â
      • ±â±â ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
    • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â

    Á¦6Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, ¿ëµµ, 2018³â-2030³â

    • ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
    • ÀÓ»ó
      • ÀÓ»ó ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • º´¿øÃ¼ °Ë»ç
      • Á¾¾çÇÐ °Ë»ç
      • Ç÷¾×°Ë»ç
      • ¾×ü »ý°Ë °Ë»ç
      • DPCR ±â¹Ý ºñħ½ÀÀû »êÀü °Ë»ç(Nipt)
      • ±âŸ
    • ¿¬±¸
      • ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³âÀ» Á¶»ç
      • Áٱ⼼Æ÷ Á¶»ç
      • DNA Ŭ·Î´× ¹× ¹è¿­ °áÁ¤
      • ÀçÁ¶ÇÕ DNA ±â¼ú
      • Èñ±Í µ¹¿¬º¯ÀÌ Å½Áö
      • À¯ÀüÀÚ ¹ßÇö
      • ´Ü¼¼Æ÷ ºÐ¼®
      • ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ºÐ¼®
      • Ä«ÇǼö º¯È­ ºÐ¼®
      • ¶óÀ̺귯¸® Á¤·®È­(NG)
      • mrna ¹× mirna ¹ßÇö
      • Á¾ ½Äº°
      • GMO ŽÁö
    • ¹ýÀÇÇÐ ¹× ±âŸ

    Á¦7Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, Áö¿ª, 2018³â-2030³â

    • ±¹°¡º° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
      • ºÏ¹Ì
      • À¯·´
      • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • ¶óƾ¾Æ¸Þ¸®Ä«
      • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

    Á¦8Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå - °æÀï ±¸µµ

    • ±â¾÷ ºÐ·ù
    • Àü·« ¸ÅÇÎ
      • ½ÅÁ¦Ç° ¹ß¸Å
      • ÆÄÆ®³Ê½Ê
      • Ãëµæ
      • Çù¾÷
      • ÀÚ±ÝÁ¶´Þ
    • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
    • ±â¾÷ °³¿ä
      • Abbott
      • Qiagen
      • Bio-Rad Laboratories, Inc.
      • Agilent Technologies, Inc.
      • Thermo Fisher Scientific, Inc.
      • Ge Healthcare
      • Biomerieux Sa
      • F. Hoffmann-La Roche Ltd
      • Fluidigm Corporation
    LSH
  • ¿µ¹® ¸ñÂ÷

    ¿µ¹®¸ñÂ÷

    Real-time PCR, Digital PCR, And End-point PCR Market Growth & Trends:

    The global real-time PCR, digital PCR, and end-point PCR market size is expected to reach USD 7.18 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. However, the real global real-time PCR, digital PCR, and end-point PCR market without the impact of the COVID-19 pandemic is expected to expand at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. Digital PCR is a novel technique for absolute quantification and analysis of minority sequences in the presence of similar majority sequences. dPCR allows for precise and sensitive nucleic acid measurement. In addition, real-time PCR provides precise and early diagnosis of diseases and rapid and targeted patient care hence anticipated to increase the demand in the coming years

    The rise in the occurrence of diseases such as lung cancer, blood cancer, and brain tumors is fueling the application expansion of the global market. According to Globocan 2020, lung cancer is the second most common cancer in Europe, with an estimated 477,534 newly diagnosed cases. Furthermore, the benefits of digital polymerase chain reaction over traditional technologies such as real-time and quantitative polymerase chain reaction are likely to drive adoption throughout the forecast period. Moreover, rising healthcare expenditures in emerging nations and the increased need for accurate molecular disease detection are propelling the market growth.

    Furthermore, the COVID-19 pandemic has increased the demand for digital PCR instruments and reagents. COVID-19 infections are detected using modern digital PCR instruments as a molecular diagnosis technique. According to the WHO, around 273 million cases have been diagnosed and roughly 5.3 million deaths have been documented worldwide due to COVID-19 as of December 2021. Moreover, in the pharmaceutical industry, digital PCR machines are also employed in R&D.

    Furthermore, advancements in technology and an increase in the number of product launches in the global market are expected to support the market growth. For instance, in June 2021, Bio-Rad Laboratories, Inc. announced the release of the PREvalence ddPCR SARS-CoV-2 waste-water quantifying kit for COVID-19 wastewater screening.

    Additionally, the increase in R&D projects for advancements in technology and an increase in collaborations between firms for the development of digital polymerase chain reactions are expected to increase the usage of PCR testing. For instance, Qiagen partnered with Atila BioSystems & Actome GmbH in January 2022 to deliver non-invasive prenatal testing (NIPT) technologies to QIAGEN's dPCR for a growing number of applications for QIAcuity. As a result, the usage of real-time and digital PCR technologies is projected to increase during the forecast period.

    Real-time PCR, Digital PCR, And End-point PCR Market Report Highlights:

    Table of Contents

    Chapter 1 Methodology and Scope

    Chapter 2 Executive Summary

    Chapter 3 Real-time PCR (qPCR) Market - Industry Outlook

    Chapter 4 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Technology Scope, 2018 - 2030 (Revenue, USD Million)

    Chapter 5 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Product Scope, 2018 - 2030 (Revenue, USD Million)

    Chapter 6 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Application Scope, 2018 - 2030 (Revenue, USD Million)

    Chapter 7 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Regional Scope, 2018 - 2030 (Revenue, USD Million)

    Chapter 8 Real-time PCR (qPCR), end point PCR, and dPCR Market - Competitive Landscape

    (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
    ¨Ï Copyright Global Information, Inc. All rights reserved.
    PC¹öÀü º¸±â